Related references
Note: Only part of the references are listed.Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
Naseema Gangat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs
Lucia Masarova et al.
BLOOD ADVANCES (2021)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm
Douglas Tremblay et al.
LEUKEMIA RESEARCH (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
Brian A. Jonas et al.
LEUKEMIA (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
Courtney L. DiNardo et al.
LANCET ONCOLOGY (2018)
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
Ayalew Tefferi et al.
LEUKEMIA (2018)
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Ibrahim Aldoss et al.
HAEMATOLOGICA (2018)
Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep and Durable Responses in Patients with AML Ineligible for Intensive Therapy
Daniel A. Pollyea et al.
BLOOD (2018)
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
Shinsuke Takagi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
John Mascarenhas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
J. S. Welch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Marina Konopleva et al.
CANCER DISCOVERY (2016)
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse
Manoj Garg et al.
BLOOD (2015)
Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN
Alessandro Andriani et al.
LEUKEMIA RESEARCH (2015)
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Talha Badar et al.
LEUKEMIA RESEARCH (2015)
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation
Haefaa Alchalby et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
X. Cahu et al.
BONE MARROW TRANSPLANTATION (2014)
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
James A. Kennedy et al.
BLOOD (2013)
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium
John Mascarenhas et al.
LEUKEMIA RESEARCH (2012)
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Li Ding et al.
NATURE (2012)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation
Stefan O. Ciurea et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
Sylvain Thepot et al.
BLOOD (2010)
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
A. Pardanani et al.
LEUKEMIA (2010)
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Anthony Green et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms
Constantine S. Tam et al.
BLOOD (2008)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
Sample size tables for exact single-stage phase II designs
RP A'Hern
STATISTICS IN MEDICINE (2001)
Share Paper
